FDA Approves SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries announced the FDA approval of its generic formulation of spironolactone and hydrochlorothiazide, which will broaden access to this essential oral antihypertensive therapy on the market. The approval is expected to intensify competitive pressure on branded competitors, driving volume growth while potentially reducing prices for patients with hypertension and edema.